Back to School: How biopharma can reboot drug development. Access exclusive analysis here

RAV12: Updated Phase I data

In an open-label, dose-escalation Phase I trial in 33 patients, RAV12 was moderately

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE